Search: id:"swepub:oai:prod.swepub.kib.ki.se:147601739" >
Targeting SARS-CoV-...
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
-
Marlin, R (author)
-
Godot, V (author)
-
Cardinaud, S (author)
-
show more...
-
Galhaut, M (author)
-
Coleon, S (author)
-
Zurawski, S (author)
-
Dereuddre-Bosquet, N (author)
-
Cavarelli, M (author)
-
Gallouet, AS (author)
-
Maisonnasse, P (author)
-
Dupaty, L (author)
-
Fenwick, C (author)
-
Naninck, T (author)
-
Lemaitre, J (author)
-
Gomez-Pacheco, M (author)
-
Kahlaoui, N (author)
-
Contreras, V (author)
-
Relouzat, F (author)
-
Fang, RHT (author)
-
Wang, ZQ (author)
-
Ellis, J (author)
-
Chapon, C (author)
-
Centlivre, M (author)
-
Wiedemann, A (author)
-
Lacabaratz, C (author)
-
Surenaud, M (author)
-
Szurgot, I (author)
-
Liljestrom, P (author)
-
Planas, D (author)
-
Bruel, T (author)
-
Schwartz, O (author)
-
van der Werf, S (author)
-
Pantaleo, G (author)
-
Prague, M (author)
-
Thiebaut, R (author)
-
Zurawski, G (author)
-
Levy, Y (author)
-
Le Grand, R (author)
-
show less...
- 2021-09-01
- 2021
- English.
-
In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 12:1, s. 5215-
- Related links:
-
https://www.nature.c...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may have distinct advantages when immunizing vulnerable individuals, children and pregnant women. Here, we present a new generation of subunit vaccines targeting viral antigens to CD40-expressing antigen-presenting cells. We demonstrate that targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to CD40 (αCD40.RBD) induces significant levels of specific T and B cells, with long-term memory phenotypes, in a humanized mouse model. Additionally, we demonstrate that a single dose of the αCD40.RBD vaccine, injected without adjuvant, is sufficient to boost a rapid increase in neutralizing antibodies in convalescent non-human primates (NHPs) exposed six months previously to SARS-CoV-2. Vaccine-elicited antibodies cross-neutralize different SARS-CoV-2 variants, including D614G, B1.1.7 and to a lesser extent B1.351. Such vaccination significantly improves protection against a new high-dose virulent challenge versus that in non-vaccinated convalescent animals.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Marlin, R
-
Godot, V
-
Cardinaud, S
-
Galhaut, M
-
Coleon, S
-
Zurawski, S
-
show more...
-
Dereuddre-Bosque ...
-
Cavarelli, M
-
Gallouet, AS
-
Maisonnasse, P
-
Dupaty, L
-
Fenwick, C
-
Naninck, T
-
Lemaitre, J
-
Gomez-Pacheco, M
-
Kahlaoui, N
-
Contreras, V
-
Relouzat, F
-
Fang, RHT
-
Wang, ZQ
-
Ellis, J
-
Chapon, C
-
Centlivre, M
-
Wiedemann, A
-
Lacabaratz, C
-
Surenaud, M
-
Szurgot, I
-
Liljestrom, P
-
Planas, D
-
Bruel, T
-
Schwartz, O
-
van der Werf, S
-
Pantaleo, G
-
Prague, M
-
Thiebaut, R
-
Zurawski, G
-
Levy, Y
-
Le Grand, R
-
show less...
- Articles in the publication
-
Nature communica ...
- By the university
-
Karolinska Institutet